Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.19 USD | +0.81% | +64.70% | +165.89% |
05-10 | Top MIdday Gainers | MT |
05-10 | Wall Street Set to Extend Gains on Thursday's Higher-Than-Expect Jobless Claims Report, Lifting US Equity Futures Pre-Bell | MT |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With a 2024 P/E ratio at 33.19 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+165.89% | 101M | - | ||
-39.29% | 3.01B | C+ | ||
+18.54% | 1.94B | - | ||
-2.22% | 1.66B | - | ||
+34.26% | 1.34B | B+ | ||
-16.73% | 965M | - | ||
-22.64% | 895M | - | C- | |
+7.22% | 827M | - | ||
-24.44% | 638M | B+ | ||
+8.49% | 516M | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SRTS Stock
- Ratings Sensus Healthcare, Inc.